Cardiome Pharma Corp. (NASDAQ:CRME) shares moved down -4.63% in last trading session and ended the day at $4.22. CRME Gross Margin is 68.10% and its has a return on assets of -49.60%. Cardiome Pharma Corp. (NASDAQ:CRME) quarterly performance is -48.35%.
On 10 March, Cardiome Pharma Corp. (NASDAQ:CRME) recorded a net loss of $24.5 million (loss per share of $1.34) for the year ended December 31, 2015, compared to a net loss of $18.2 million (loss per share of $1.12) for the year ended December 31, 2014. The net loss in 2015 was negatively impacted by foreign exchange translation and a number of one-time non-recurring factors. Revenue for the year ended December 31, 2015 was $20.9 million compared to revenue of $30.0 million for the year ended December 31, 2014. The decrease was due to foreign exchange translation on Euro denominated revenue ($2.0 million), the timing of distributor sales which included a distributor’s 2015 order ($1.7 million) being delayed to 2016, a decrease in AGGRASTAT® sales due to generic competition versus the previous year and a reserve recorded against revenue in relation to disputed historical product returns with a distributor.
BroadVision, Inc. (NASDAQ:BVSN) ended the last trading day at $6.36. Company weekly volatility is calculated as 3.17% and price to cash ratio as 0.96. BroadVision, Inc. (NASDAQ:BVSN) showed a weekly performance of 1.27%.
On 15 March, Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) shares moved down -1.78% and was closed at $8.28. Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) year to date (YTD) performance is -33.65%.
Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) reported Net loss for 2015 was $21.9 million compared to a net loss of $24.0 million for 2014. The decrease in net loss was primarily due to the reduction in research and development expenditures over the second half of 2015.
OvaScience, Inc. (NASDAQ:OVAS) shares moved down -4.34% in last trading session and ended the day at $7.72. OVAS has a return on assets of -46.40%. OvaScience, Inc. (NASDAQ:OVAS) quarterly performance is -18.22%.
OvaScience Inc. (NASDAQ:OVAS) announced that Company management present at the Cowen and Company 36th Annual Health Care Conference on Wednesday, March 9, 2016 at 8:00 a.m. ET at the Boston Marriott Copley Place in Boston, MA.
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) caters to the Healthcare space. Its weekly performance is -18.53%. On the last day of trading company shares ended up at $8.09.
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) reported a net loss of $16.8 million for the fourth quarter of 2015 and $48.5 million for the year ended December 31, 2015, compared to a net loss of $74.3 million and $84.0 million for the comparable periods in 2014. The net loss amounts for the 2014 periods included a charge of $43.2 million incurred in the fourth quarter of 2014 in conjunction with the ARIAD license restructure transaction and a non-cash accounting charge of $24.4 million recorded for the change in fair value of warrants that were exercised in conjunction with Bellicum’s December 2014 initial public offering, of which $23.2 million was a fourth quarter expense.